José Locia Espinoza, Alicia Andrade Ortega, Patricia Elisa Molina Prior, Gloria Molina Rodríguez, Emma Virginia Herrera Huerta, Magda Olivia Pérez Vásquez, Abraham Heriberto Soto Cid
Revista Mexicana de Ciencias Farmacéuticas 2017, 48 (1)
Resumen
La Diabetes Mellitus tipo 2 (DM-2) es un trastorno metabólico caracterizado por la incapacidad del organismo para obtener energía a partir de la glucosa. Los pacientes diabéticos suelen manifestar otros trastornos y estar polimedicados, siendo factible realizarles el seguimiento farmacoterapéutico (SFT). Se realizó SFT a 86 pacientes con DM-2 hospitalizados en Medicina Interna del Centro de Alta Especialidad “Dr. Rafael Lucio” utilizando el método Dáder. Los Problemas Relacionados con Medicamentos (PRM) predominantes fueron las Interacciones. Los Resultados Negativos asociados a la Medicación (RNM) de mayor frecuencia fueron la inefectividad e inseguridad no cuantitativas. Se realizaron 176 intervenciones, predominando las de educación al paciente y realizándose principalmente ante éste. Es posible que los PRM y RNM encontrados tengan relación con la polifarmacia y la edad de los pacientes.
Abstract
Diabetes Mellitus type 2 (DM-2) is a metabolic disorder characterized by the inability of the body to obtain energy from glucose. Diabetic patients tend to manifest other disorders and be polymedicated, which make it possible to carry out the Pharmacotherapy follow-up (PF). PF was performed in 86 patients with DM-2 who were hospitalized in Internal Medicine section of the High Specialty Center “Dr. Rafael Lucio” for which the Dader method was used. The predominant Drug Related Problems (DRPs) were Interactions. The most frequently associated Negative Outcomes associated whit Medication (NOMs) were non-quantitative ineffectiveness and insecurity. One hundred seventy-six interventions were performed, predominantly those of pharmaceutical orientation to the patient and being performed mainly before this one. It is possible that the DRPs and NOMs that were founded are related to the polypharmacy and the age of the patients.